Clinical Trials Logo

Acute Interstitial Nephritis clinical trials

View clinical trials related to Acute Interstitial Nephritis.

Filter by:
  • None
  • Page 1

NCT ID: NCT05233241 Not yet recruiting - Clinical trials for Acute Interstitial Nephritis

Identification of the Causative Drug in Drug-induced Acute Interstitial Nephritis

IDENIAM
Start date: July 2022
Phase: N/A
Study type: Interventional

Drug-induced acute interstitial nephritis (DAIN) is a rare entity characterized by acute renal failure linked to inflammation of the renal parenchyma secondary to allergenic drug exposure. Treatment is based primarily on the precise identification of the causative drug and its final elimination. Currently, the identification of the causative drug is based on clinical presumption. There is no test to formally identify the causative drug. On the other hand, in-vitro allergological tests (lymphocyte transformation test in particular) have been developed in the course of immuno-allergic drug toxiderma linked to delayed type IV hypersensitivity to identify the causal drug. These tests have not been studied during DAIN, but their value in drug-induced eruption is indisputable. The objective of our study is to determine whether in vitro allergy tests can identify the causative drug during DAIN. If the in vitro tests fail, they will be supplemented by allergological skin tests.

NCT ID: NCT04343417 Enrolling by invitation - Acute Kidney Injury Clinical Trials

Biorepository to Support Research in Kidney Diseases

Start date: July 28, 2020
Phase:
Study type: Observational [Patient Registry]

To support advances in the understanding of pathophysiology and therapies of kidney diseases by creating a BioBank of kidney tissue, DNA, plasma, and urine from patients with kidney diseases.

NCT ID: NCT01893658 Withdrawn - Clinical trials for Acute Interstitial Nephritis

Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

Start date: June 1, 2018
Phase: Phase 2
Study type: Interventional

The investigators goal is to evaluate the role of XOLAIR® in treatment of Acute Tubulointerstitial Nephritis (AIN) with the goal of shortening the duration and dose of prednisone for treatment of drug-induced AIN. Currently there is no good treatment for drug-induced AIN. Prednisone is the standard treatment but is associated with many side-effects when used long-term and at high doses.